Institutional investors hold a majority ownership of BIIB through the 90.37% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended June 2017, these large investors purchased a net $1.7 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Bought 830.6 Thousand shares of Biogen